Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

GCSF administration can reduce side effects of cancer neurobastoma in children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

21 Jul 2010

StemCell Holding leads CHF 20 million investment in Pantec Biosolutions

Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the closing of a CHF 20 million investment achieved by two financing rounds. The StemCell Holding AG, an Austrian investment company in the life sciences sector, acted as lead investor.

20 Jul 2010

KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.

20 Jul 2010

Researchers identify a stress hormone in sea lamprey

Michigan State University researchers are the first to identify a stress hormone in the sea lamprey, using the 500 million-year-old species as a model to understand the evolution of the endocrine system.

20 Jul 2010

Novo Nordisk completes patient enrollment in A1chieve study for type 2 diabetes management

Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.

From Novo Nordisk 20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Here are highlights from the July issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required.

20 Jul 2010

Researchers discover new gene regulation, DNA behavior of breast cancer cells

Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.

20 Jul 2010

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

From Novo Nordisk 19 Jul 2010

Resveratrol concentration impacts cancer risk mitigation: Study

Agricultural Research Service (ARS) chemist Thomas Wang, who specializes in cancer prevention research, has reported evidence that for some dietary compounds, length of exposure over time may be key to whether or not ingestion leads to a beneficial, or detrimental, effect.Scientists do not know exactly why one person develops cancer and another does not. But they do know that certain nutrients might increase or decrease cancer risk. There are "layers" of factors involved in the development of cancer, and Wang is studying the layers involving peoples' diet complexity and gene expression.

17 Jul 2010

New research reports evaluating nephrology market in Europe released

BioTrends Research Group, Inc. has released two new syndicated market research reports evaluating the nephrology market in Europe. The reports, TreatmentTrends: Renal Anemia and TreatmentTrends: Bone and Mineral Metabolism, are derived from the responses of over 200 European nephrologists polled in May and June, 2010 regarding their approach to managing renal anemia and bone and mineral disturbances in their dialysis and chronic kidney disease patients.

16 Jul 2010

Two-thirds of world's population are vitamin D-insufficient or deficient

Vitamin D surfaces as a news topic every few months. How much daily vitamin D should a person get? Is it possible to have too much of it? Is exposure to the sun, which is the body's natural way of producing vitamin D, the best option? Or do supplements suffice?

16 Jul 2010

Researchers study recovery patterns of children affected by Hurricane Katrina

Rebuilding schools after Hurricane Katrina and providing supportive environments and relationships have helped many children reduce their levels of overall trauma from the hurricane that devastated the Gulf Coast in August 2005, according to a new study. A second study found that girls had distinct stress reactions from boys in the aftermath of the storm.

16 Jul 2010

An overview of heart palpitations from Mayo Clinic

Almost everyone feels occasional heart palpitations -- a change in the heart's rhythm. Palpitations range from what feels like a skip, flip or bump in the heart's rhythm to a sustained, racing heartbeat.

16 Jul 2010

High blood pressure, diabetes leads to CKD

People with diabetes and high blood pressure need to take care of their kidneys. According to the July issue of Mayo Clinic Women's HealthSource, chronic kidney disease (CKD) is a growing problem in the United States. The most common causes are diabetes and high blood pressure

16 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

Type 1 diabetes affects athletic performance, new study finds

A new study led by York University researchers finds that young athletes with Type 1 diabetes may experience a marked decrease in performance as a result of their blood sugar levels.

15 Jul 2010

Adolescents with good physical condition experience better appetite control, energy expenditure: Study

Adolescents of ages between 12 and 17, with a good physical condition and regular physical activity present increased levels of insulin and leptin, which are hormones involved in the development of diabetes, appetite control and energy expenditure. This was the conclusion drawn from a study recently conducted at the Department of Physiology of the University of Granada. Further, after thorough analysis of a number of scientific studies, they also concluded that physical activity and physical condition are negatively associated to adolescents' body fat.

15 Jul 2010

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Watson Pharmaceuticals, Inc. today announced an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals, Inc., a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero's Recombinant Follicle Stimulating Hormone. The product is currently in preclinical development as a biosimilar molecule for the treatment of female infertility.

15 Jul 2010

Dementia varies among diabetic, non-diabetic patients: Research

Researchers from Mayo Clinic's Florida campus say that dementia in some diabetics appears to be caused often by vascular disease in the brain, and the dementia that develops in people without diabetes is more likely associated with deposition of the plaque seen in people with Alzheimer's disease

15 Jul 2010